Track topics on Twitter Track topics that are important to you
NeoImmuneTech (NIT), along with its parent company Genexine, has signed an agreement with Roche to perform a Phase Ib/IIa immuno-oncology...Read More... The post NeoImmuneTech to conduct HyLeukin-7 an...
Roche agreed to conduct a combination study of its Tecentriq (atezolizumab) with NeoImmuneTech Inc.’s HyLeukin-7 (IL-7-hyFc) in three high-risk skin cancers: melanoma, Merkel cell carcinoma, and cut...
NeoImmuneTech Announces a Clinical Trial Collaboration with a Global Leading Pharmaceutical Company to Evaluate HyLeukin-7 in Combination with a PD-L1 Checkpoint Inhibitor in Advanced High-Risk Skin Cancers
NeoImmuneTech (NIT), an immunotherapy drug development company focused on advanced cancer treatments, and its parent company Genexine, have entered into an agreement with ...
We have published hundreds of NeoImmuneTech news stories on BioPortfolio along with dozens of NeoImmuneTech Clinical Trials and PubMed Articles about NeoImmuneTech for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of NeoImmuneTech Companies in our database. You can also find out about relevant NeoImmuneTech Drugs and Medications on this site too.